Shares of Shockwave Medical Inc (NASDAQ:SWAV) have been assigned an average broker rating score of 3.00 (Hold) from the three analysts that provide coverage for the stock, Zacks Investment Research reports. Three investment analysts have rated the stock with a hold rating.

Brokers have set a 12 month consensus price target of $34.00 for the company and are predicting that the company will post ($0.52) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Shockwave Medical an industry rank of 84 out of 255 based on the ratings given to its competitors.

A number of equities analysts have recently weighed in on the company. Wells Fargo & Co assumed coverage on Shockwave Medical in a report on Monday, April 1st. They issued a “market perform” rating and a $33.00 target price on the stock. Bank of America assumed coverage on Shockwave Medical in a report on Monday, April 1st. They issued a “neutral” rating and a $37.00 target price on the stock. Finally, Morgan Stanley assumed coverage on Shockwave Medical in a report on Monday, April 1st. They issued an “equal weight” rating and a $32.00 target price on the stock.

NASDAQ SWAV traded up $1.56 on Monday, hitting $31.68. 170,700 shares of the company were exchanged, compared to its average volume of 273,165. Shockwave Medical has a twelve month low of $24.58 and a twelve month high of $43.39.

In other Shockwave Medical news, insider James E. Flynn bought 30,000 shares of the company’s stock in a transaction dated Monday, March 11th. The shares were bought at an average price of $17.00 per share, for a total transaction of $510,000.00. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.

Shockwave Medical Company Profile

ShockWave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters or treating below-the-knee peripheral artery disease.

Featured Story: How to find the components of the quick ratio

Get a free copy of the Zacks research report on Shockwave Medical (SWAV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Shockwave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shockwave Medical and related companies with MarketBeat.com's FREE daily email newsletter.